The 5-year survival rate of small hepatocellular carcinoma with standardized treatment has reached more than 50%, or even greater than 70%. For many years, liver cancer has been called the “king of cancers” and regarded as an incurable disease, but nowadays, advances in medical technology have made this persistent disease partially curable and made the dream of liver cancer patients to live beyond 5 years come true, which is a remarkable achievement. Numerous studies have shown that early detection, early diagnosis, early treatment and standardized treatment of liver cancer are the basis and key to achieve good results, and the difference between early and late treatment is huge. Small liver cancer is also called subclinical liver cancer and early liver cancer. It refers to a single cancer nodule with diameter not more than 3 cm or the sum of two cancer nodules with diameter not more than 3 cm without obvious symptoms and signs. The tumor nodules are mostly spherical in shape, with envelope and clear boundary, and have not yet spread and invaded blood vessels and surrounding tissues. Regardless of surgical resection, ablation therapy and interventional therapy, the effect is better and it is possible to achieve complete eradication. The liver has a strong compensatory function and is the most capable organ in the human body to “bear the burden”. As a result, liver cancer starts insidiously and has no or no obvious symptoms in the early stage, most patients have already reached advanced stage or distant metastasis when diagnosed, which makes treatment difficult and prognosis very poor. Once the diagnosis of liver cancer was confirmed before the 1990s, most patients did not live for half a year, and more often not in one or two months, which is why liver cancer was given the title of “King of Cancer”. What can be done to restrain this disease? Active prevention is the best strategy and scientific treatment is the guarantee. We should do well in “three investigations and three early treatments”: tertiary screening, early prevention, early diagnosis and early treatment. Three-level screening: According to the risk level of liver cancer in people who are prone to liver cancer, there are three categories: the first category is high-risk group, such as patients with hepatitis B or C who have progressed to cirrhosis; the second category is medium-risk group, such as patients with chronic viral hepatitis, but without family history of cirrhosis and liver cancer. The third category is the low-risk group, patients with non-viral causes of hepatitis without cirrhosis. The three-level screening means that different examinations are conducted according to the three categories of people. The general high-risk group will have relevant tests (liver function, methemoglobin and ultrasound) every three months; the medium-risk group will have tests at least every six months; and the low-risk group will have relevant tests every year. When a suspicious case is detected, further CT, MRI or arteriography should be performed until liver cancer is confirmed or excluded. With the development of medical science, the technology of early diagnosis of liver cancer has advanced tremendously. Such as hematological examination, imaging examination, especially the mature application of ultrasonography and real-time guided precise positioning liver puncture biopsy technology, which can perform pathological examination on liver tissues obtained by puncture. With the help of the microscope, “ants can be seen as elephants”, which is really a “golden eye and a clear understanding”, can observe the cell morphology, determine the nature of the lesion, provide an authoritative diagnostic basis, and become the “gold standard The “gold standard”. In the past two years, through follow-up screening, liver histopathological examination and hepatic arteriography, nearly 100 patients with small hepatocellular carcinoma less than 2 cm have been diagnosed and treated at an early stage, with very good results. Early treatment: including liver transplantation, surgical resection, embolization, ablation and other treatment methods, must be based on the principle of “early, minimally invasive, targeted and comprehensive”, avoid over-treatment or under-treatment, control the tumor to the greatest extent, and strive for eradication. Surviving for five years was once the luxury dream of many liver cancer patients. With the progress of medical science and the improvement of treatment measures, more and more liver cancer patients can live for five years with ease.